AB Science's AD Program Gets $11M in Project Funds
By Cormac Sheridan
Wednesday, July 24, 2013
AB Science SA received a €5.9 million (US$7.8 million) funding boost for its Phase III development program of masitinib in Alzheimer's disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.